Cargando…
The Effect of Sodium Channel Blocker, Mexiletine, on Body Weight in Type 2 Diabetes Patients with Visceral Obesity
OBJECTIVE: Mexiletine is an anti-arrhythmic agent also used for the treatment of painful diabetic neuropathy. In this study, the effect of mexiletine on body weight was evaluated in type 2 diabetes patients with diabetic neuropathy exhibiting visceral obesity. METHODS: Type 2 diabetes patients with...
Autor principal: | Ueno, Naohiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343451/ https://www.ncbi.nlm.nih.gov/pubmed/30733634 http://dx.doi.org/10.1177/1179551418825049 |
Ejemplares similares
-
Molecular Modeling of Cardiac Sodium Channel with Mexiletine
por: Zhorov, Boris S.
Publicado: (2022) -
Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker
por: Delnavaz Shahr, Amirali, et al.
Publicado: (2019) -
Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential
por: De Bellis, Michela, et al.
Publicado: (2018) -
Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine
por: Desaphy, Jean-François, et al.
Publicado: (2012) -
Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3
por: Li, Gang, et al.
Publicado: (2020)